Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPCByOrazio Caffo, MDJune 17th 2019Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.